Core Points - Fresenius Medical Care (FME) is partnering with the Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) in Mexico to extend High-Volume Hemodiafiltration (HighVolumeHDF) access to low-income patients without medical coverage [1][2] - The pilot program aims to provide chronic kidney disease patients with high-quality treatments that were previously inaccessible, marking a significant advancement in CKD care in Mexico [3] - The initiative has already provided HighVolumeHDF treatment to 240 new patients and 410 regular patients covered by insurance [5][11] Company Initiatives - A two-year contract has been signed to install 150 Fresenius Medical Care 5008S CorDiax systems in CCINSHAE centers in Mexico City and its metropolitan area [2] - The technology offers both standard hemodialysis and HighVolumeHDF, which has shown improved patient well-being and cost-effectiveness [4] - The company is committed to expanding HighVolumeHDF therapy to all markets, including the U.S., where it has received FDA clearance for its 5008X Hemodialysis System [9][10][11] Clinical Evidence - High-Volume Hemodiafiltration has been supported by clinical studies, including the CONVINCE Trial, which reported a 23% reduction in all-cause mortality for patients treated with HighVolumeHDF compared to standard high-flux hemodialysis [7]